Andrea E. Wahner-Hendrickson

611 total citations · 1 hit paper
6 papers, 363 citations indexed

About

Andrea E. Wahner-Hendrickson is a scholar working on Molecular Biology, Reproductive Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andrea E. Wahner-Hendrickson has authored 6 papers receiving a total of 363 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Molecular Biology, 3 papers in Reproductive Medicine and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andrea E. Wahner-Hendrickson's work include Ovarian cancer diagnosis and treatment (3 papers), Advanced Breast Cancer Therapies (2 papers) and Chromatin Remodeling and Cancer (2 papers). Andrea E. Wahner-Hendrickson is often cited by papers focused on Ovarian cancer diagnosis and treatment (3 papers), Advanced Breast Cancer Therapies (2 papers) and Chromatin Remodeling and Cancer (2 papers). Andrea E. Wahner-Hendrickson collaborates with scholars based in United States. Andrea E. Wahner-Hendrickson's co-authors include Sara M. Tolaney, Julie R. Graham, Gerburg M. Wulf, John K. Erban, Sujata Arora, Filipa Lynce, Georgia A. McCann, Carey K. Anders, Monica Mita and Patrick M. Dillon and has published in prestigious journals such as Gynecologic Oncology, JAMA Oncology and Journal of the National Comprehensive Cancer Network.

In The Last Decade

Andrea E. Wahner-Hendrickson

4 papers receiving 359 citations

Hit Papers

Open-label Clinical Trial of Niraparib Combined With Pemb... 2019 2026 2021 2023 2019 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
    2019 314 citations Shaveta Vinayak, Sara M. Tolaney et al. JAMA Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrea E. Wahner-Hendrickson United States 4 302 118 83 82 67 6 363
S. M. Domchek United States 8 317 1.0× 143 1.2× 52 0.6× 73 0.9× 98 1.5× 21 400
Valerie Bowering Canada 10 310 1.0× 168 1.4× 51 0.6× 35 0.4× 37 0.6× 28 378
Jeff Isaacson United States 5 258 0.9× 116 1.0× 50 0.6× 27 0.3× 21 0.3× 8 284
Philip Rowe United Kingdom 6 328 1.1× 152 1.3× 39 0.5× 24 0.3× 44 0.7× 7 389
E. Hitt Nichols United States 3 231 0.8× 83 0.7× 96 1.2× 20 0.2× 19 0.3× 5 267
Berthold Gierke Germany 8 105 0.3× 148 1.3× 21 0.3× 32 0.4× 72 1.1× 12 277
Stephanie Royer‐Joo United States 10 139 0.5× 186 1.6× 53 0.6× 56 0.7× 40 0.6× 23 303
D. Toppmeyer United States 6 295 1.0× 116 1.0× 28 0.3× 39 0.5× 120 1.8× 9 383
Edyta Vieth United States 7 72 0.2× 267 2.3× 26 0.3× 38 0.5× 113 1.7× 7 328
Shiaw-Yih Lin United States 6 166 0.5× 218 1.8× 71 0.9× 46 0.6× 89 1.3× 7 326

Countries citing papers authored by Andrea E. Wahner-Hendrickson

Since Specialization
Citations

This map shows the geographic impact of Andrea E. Wahner-Hendrickson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrea E. Wahner-Hendrickson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrea E. Wahner-Hendrickson more than expected).

Fields of papers citing papers by Andrea E. Wahner-Hendrickson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrea E. Wahner-Hendrickson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrea E. Wahner-Hendrickson. The network helps show where Andrea E. Wahner-Hendrickson may publish in the future.

Co-authorship network of co-authors of Andrea E. Wahner-Hendrickson

This figure shows the co-authorship network connecting the top 25 collaborators of Andrea E. Wahner-Hendrickson. A scholar is included among the top collaborators of Andrea E. Wahner-Hendrickson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrea E. Wahner-Hendrickson. Andrea E. Wahner-Hendrickson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

6 of 6 papers shown
1.
Gien, Lilian T., Danielle Enserro, Matthew S. Block, et al.. (2024). Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016. Gynecologic Oncology. 186. 61–68. 10 indexed citations
2.
O’Cearbhaill, Roisin E., Austin Miller, Robert A. Soslow, et al.. (2023). A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283. Gynecologic Oncology. 176. 16–24. 3 indexed citations
3.
Ehlers, Shawna L., Lisa M. Gudenkauf, Elizabeth L. Kacel, et al.. (2023). Real-World Implementation of Best-Evidence Cancer Distress Management: Truly Comprehensive Cancer Care. Journal of the National Comprehensive Cancer Network. 21(6). 627–635.
4.
Wahner-Hendrickson, Andrea E. & John B. Bundrick. (2019). Clinical Pearls in Oncology 2019. Disease-a-Month. 65(11). 100863–100863.
5.
Vinayak, Shaveta, Sara M. Tolaney, Lee S. Schwartzberg, et al.. (2019). Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. JAMA Oncology. 5(8). 1132–1132. 314 indexed citations breakdown →
6.
Colón‐Otero, Gerardo, S. John Weroha, Nathan R. Foster, et al.. (2017). Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers. Gynecologic Oncology. 146(1). 64–68. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S. M. Domchek Breakdown of academic impact, for papers by Valerie Bowering Breakdown of academic impact, for papers by Jeff Isaacson Breakdown of academic impact, for papers by Philip Rowe Breakdown of academic impact, for papers by E. Hitt Nichols Breakdown of academic impact, for papers by Berthold Gierke Breakdown of academic impact, for papers by Stephanie Royer‐Joo Breakdown of academic impact, for papers by D. Toppmeyer Breakdown of academic impact, for papers by Edyta Vieth Breakdown of academic impact, for papers by Shiaw-Yih Lin
Rankless by CCL
2026